Revvity's euroimmun unveils new fully automated instrument for specialty testing

Waltham, mass.--(business wire)--revvity, inc. (nyse: rvty), today announced the launch of its new ids i20™ analytical random access platform from euroimmun, enabling full automation of chemiluminescence immunoassays (chlia). the ids i20 platform is a ce marked and fda listed device that allows laboratories to consolidate multiple specialty tests on a unique single instrument with greater reagent capacity and higher test throughput compared to existing offerings. the highly versatile ids i20 in.
RVTY Ratings Summary
RVTY Quant Ranking